[Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension]

Med Clin (Barc). 2002 Jun 1;118(20):761-6. doi: 10.1016/s0025-7753(02)72524-4.
[Article in Spanish]

Abstract

Background: Primary pulmonary hypertension is a poorly understood disease with a difficult treatment.

Patients and method: Retrospective study of a series of 44 patients suffering from pulmonary hypertension who were studied in our center between 1992 and 2000.

Results: At diagnosis, 6 (13%) patients were classified as having NYHA functional class I, 11 (25%) had class II, 25 (57%) had class III, and 2 had class IV. Mean pulmonary artery systolic pressure by echo-doppler was 92 (range: 43-154) mmHg. Basal right catheterization showed a mean (SD) pulmonary artery pressure of 58 (18) mmHg, total basal pulmonary resistances of 1679 (1,071) din/cm2 and cardiac index of 2.2 (1) 1/minute/m2. Five patients improved with anticoagulation and calcium channel blockers therapy. Since 1998, 11 patients had been treated with continuous endovenous epoprostenol, yet only 3 (27%) had significant clinical improvement. Survival at 5 years after diagnosis was 56%. At the end of study, 7 (70%) out of 10 patients who underwent pulmonary transplantation were alive (mean: 34, range: 3-62 months).

Conclusions: Pulmonary hypertension is a disease with a poor prognosis. However, treatment with prostaglandins and pulmonary transplantation may lead to encouraging results.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Epoprostenol / administration & dosage
  • Epoprostenol / therapeutic use
  • Female
  • Follow-Up Studies
  • Hemodynamics
  • Humans
  • Hypertension, Pulmonary* / diagnosis
  • Hypertension, Pulmonary* / drug therapy
  • Hypertension, Pulmonary* / mortality
  • Hypertension, Pulmonary* / physiopathology
  • Lung Transplantation
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Retrospective Studies
  • Time Factors

Substances

  • Anticoagulants
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Platelet Aggregation Inhibitors
  • Epoprostenol